Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
22 mai 2023 06h30 HE
|
Oculis SA
DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with...
Oculis Co-founders Selected as Finalists in European Inventor Award 2023
11 mai 2023 08h00 HE
|
Oculis SA
Professors Einar Stefánsson and Thorsteinn Loftsson, Oculis’ co-founders, nominated in ‘Research’ category of prestigious European Patent Office awardsNominated in recognition of research developing...
Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
26 avr. 2023 07h00 HE
|
Oculis SA
Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team...
Oculis to Participate at Upcoming Investor Conferences
05 avr. 2023 07h00 HE
|
Oculis SA
ZUG, Switzerland and BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
04 avr. 2023 07h00 HE
|
Oculis SA
ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
22 mars 2023 07h00 HE
|
Oculis SA
ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
16 mars 2023 09h45 HE
|
Oculis SA
Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval.If approved, OCS-01 has the potential to become the first once-daily, topical,...
Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer
01 sept. 2020 08h00 HE
|
Oculis SA
LAUSANNE, Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives...
Oculis Appoints Dr. Frédéric Pilotaz as Vice President of Technology & Pharmaceutical Sciences
21 avr. 2020 08h00 HE
|
Oculis SA
LAUSANNE, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...
Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer
03 mars 2020 08h00 HE
|
Oculis SA
LAUSANNE, Switzerland, March 03, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...